CARDIFF ONCOLOGY, INC. financials

CRDF CIK 0001213037

Source: EDGAR filings · Built 2026-06-02T02:44:14Z

Key metrics by reporting period

Up to six most-recent periods side-by-side. Rows are the curated key lines — revenue, margins, cash, debt, equity, cash-flow totals, plus the derived and valuation metrics we compute on top. For every tag a filer reported in one period, use the single-filing drilldown below.

Derived Metrics

Concept FY 2025FY 2024FY 2023FY 2022FY 2021FY 2020
Free Cash Flow -37.97M -37.77M -31.47M -34.83M -23.25M -16.53M
EBITDA -48.60M -48.25M -45.01M -39.67M -28.40M -18.62M
Working Capital 43.73M 81.63M 66.97M 103.48M 139.57M 127.24M
Net Debt -16.64M -49.95M -19.51M -13.63M -8.82M -130.11M
Operating Margin -8256.32% -7123.13% -9305.74% -10337.31% -8037.60% -5214.75%
Net Margin -7732.04% -6651.68% -8492.01% -10026.94% -7880.50% -5275.14%
Return on Equity (ROE) -101.02% -54.77% -59.42% -36.40% -20.15% -15.06%
Return on Assets (ROA) -74.09% -46.74% -50.76% -33.31% -18.92% -14.33%
Current Ratio 3.67× 7.08× 7.41× 14.25× 22.28× 21.79×
Debt-to-Equity 0.02× 0.02× 0.03× 0.03× 0.02× 0.01×
Effective Tax Rate 0.00% 0.00%
Cash Conversion Ratio 0.83× 0.83× 0.75× 0.87× 0.81× 0.84×
Accruals Ratio -0.13× -0.08× -0.13× -0.04× -0.04× -0.02×
SBC % of Revenue 960.03% 696.93% 923.98% 1102.59% 900.84% 482.24%
CapEx Coverage -861.89× -471.16× -53.07× -33.62× -112.39× -77.32×
Free Cash Flow Per Share $-0.57 $-0.79 $-0.70 $-0.80 $-0.60 $-0.79

Valuation Metrics

Concept FY 2025FY 2024FY 2023FY 2022FY 2021FY 2020
P/S 323.67× 422.71× 135.50× 162.04× 702.52× 1807.90×
P/B 4.23× 3.48× 0.95× 0.59× 1.80× 5.16×

Income Statement

Concept FY 2025FY 2024FY 2023FY 2022FY 2021FY 2020
Revenue from Contract with Customer, Excluding Assessed Tax 593.00K 683.00K 488.00K 386.00K 359.00K 366.00K
Revenues 365.99K
Research and Development Expense 27.10M 17.40M 11.24M
Selling, General and Administrative Expense 14.22M 12.48M 13.04M 13.18M 11.84M 8.22M
Operating Expenses 49.55M 49.33M 45.90M 40.29M 29.21M 19.45M
Operating Income (Loss) -48.96M -48.65M -45.41M -39.90M -28.86M -19.09M
Income Tax Expense (Benefit) 0 0 0 0 0 0
Net Income (Loss) Attributable to Parent -45.85M -45.43M -41.44M -38.70M -28.29M -19.31M
Earnings Per Share, Basic $-0.69 $-0.95 $-0.93 $-0.89 $-0.73 $-1.08
Weighted Average Number of Shares Outstanding, Basic 66.84M 47.65M 44.68M 43.60M 39.03M 20.88M
Earnings Per Share, Diluted $-0.69 $-0.95 $-0.93 $-0.89 $-0.73 $-1.08
Weighted Average Number of Shares Outstanding, Diluted 66.84M 47.65M 44.68M 43.60M 39.03M 20.88M

Balance Sheet

Concept FY 2025FY 2024FY 2023FY 2022FY 2021FY 2020
Cash and Cash Equivalents, at Carrying Value 17.47M 51.47M 21.66M 16.35M 11.94M 130.98M
Assets, Current 60.13M 95.05M 77.41M 111.28M 146.13M 133.36M
Assets 61.88M 97.19M 81.64M 116.19M 149.54M 134.73M
Liabilities, Current 16.39M 13.43M 10.44M 7.81M 6.56M 6.12M
Liabilities 16.50M 14.24M 11.90M 9.85M 9.13M 6.57M
Stockholders' Equity Attributable to Parent 45.39M 82.95M 69.74M 106.34M 140.42M 128.16M
Common Stock, Shares, Outstanding 68.31M 66.52M 44.68M 44.68M 41.96M 36.78M

Cash Flow Statement

Concept FY 2025FY 2024FY 2023FY 2022FY 2021FY 2020
Net Cash Provided by (Used in) Operating Activities -37.92M -37.69M -30.89M -33.82M -23.04M -16.32M
Payments to Acquire Property, Plant, and Equipment 44.00K 80.00K 582.00K 1.01M 205.00K 211.00K
Net Cash Provided by (Used in) Investing Activities 1.34M 13.73M 36.20M 38.15M -131.45M -211.00K
Net Cash Provided by (Used in) Financing Activities 2.58M 53.78M 0 75.00K 35.45M 137.31M

Raw XBRL tagging for a single filing

Every us-gaap and custom concept the filer tagged for one fiscal period, grouped by statement. Start here when a number in the trend table above surprises you and you want to see the exact tag behind it. Derived and valuation rows are omitted here because they already appear in the trend table.

Most recent filing shown by default.

Compare filings side-by-side

Diff any two filings with deltas and added / removed tags.

Immaterial rows are USD line items under 1% of the period's revenue — the noise floor below which a single tag rarely moves the investment thesis. Revenue is read from the filer's top-line concept (Revenues / RevenueFromContractWithCustomerExcludingAssessedTax, with a fallback chain). Non-USD rows, rows without a numeric value, and every row on a filing with no identifiable revenue anchor stay visible. Flip the switch off to see every tag the filer reported for the period.

Loading filing details…

Methodology

All facts on this page come straight from SEC EDGAR XBRL company-facts filings (CRDF CIK 0001213037), grouped by financial statement using FASB's base us-gaap presentation taxonomy. Filers may re-parent concepts onto different statements in their own extension taxonomy, so a handful of rows can show up under a different statement than on the actual 10-K / 10-Q; custom concepts and any we couldn't map fall into Other. Hover a cell to see the fully-qualified concept name and the filer's description.

For the full methodology — statement grouping, the Other bucket, derived metrics, and fact tooltips — see the methodology reference for the statement grouping, the "Other" bucket, derived metrics, and fact tooltips.

Related tickers

RMNI

RIMINI STREET, INC.

AXSM

AXSOME THERAPEUTICS, INC.

HTFL

Heartflow, Inc.